UnitedHealth Group Incorporated Stock Price Targets

Comprehensive analysis of short, mid, and long-term price targets for UnitedHealth Group Incorporated (UNH).

Back to Analysis Hub

Give me a comprehensive price target analysis for UnitedHealth Group Incorporated (UNH).

Below is a comprehensive analysis for UnitedHealth Group Incorporated (UNH) as of 2025-10-07, including the requested horizontal target lines drawn on the price chart and a structured investment thesis with data-driven detail.

Drawing confirmation

  • Low Target line drawn at 198.00 (color: blue) from 2025-10-07 to 2025-11-06.
  • Median Target line drawn at 331.00 (color: green) from 2025-10-07 to 2025-11-06.
  • High Target line drawn at 626.00 (color: red) from 2025-10-07 to 2025-11-06.

Technical note: The lines extend 30 days into the future from today's date, as requested.

Executive Summary

  • Investment thesis: UNH remains a dominant player in the US health care ecosystem with a large and diversified revenue base, stable cash flows, and an attractive dividend. Valuation metrics are modest relative to growth peers, and the stock trades at a forward multiple that implies modest growth expectations, with potential upside if earnings quality improves and healthcare demand remains resilient.
  • Current stance: Neutral to modestly bullish near-term given a strong balance sheet, expanding cash generation, and a defensive business model, but near-term technicals show overbought signals that could lead to consolidation or a pullback toward the median target.
  • Key upside catalysts: sustained earnings momentum, higher membership in MA plans, continued cost discipline, strong free cash flow, successful capital allocation (buybacks/dividends), and favorable regulatory tailwinds for US healthcare services.

Fundamental Analysis

  • Valuation and size
    • Current price: 358.77
    • Market cap: 324.93B
    • Enterprise value: 383.46B
    • Trailing P/E: 15.54
    • Forward P/E: 11.999
    • Price-to-Book: 3.428
    • PEG ratio: not provided (null)
    • Beta: 0.478 (defensive, lower volatility relative to market)
  • Profitability and margins
    • Profit margin: 5.04%
    • Gross margin: 20.84%
    • Operating margin: 4.61%
    • Return on equity (ROE): 21.65%
    • Return on assets (ROA): 6.46%
  • Balance sheet and liquidity
    • Total cash: 32.02B
    • Total debt: 79.19B
    • Debt to equity: 75.58
    • Dividend yield: 2.45% (five-year average dividend yield: 1.47%)
  • Growth and cash flow (high-level)
    • FCF/cash flow indicators aren’t explicitly provided; however, cash balance is meaningful and debt levels are sizable but manageable given robust operating cash flows in a large healthcare services business.
  • Competitive and risk context
    • Defensive, regulated market with recurring revenue streams (Medicare/MA type lines, commercial plans, and services).
    • Leverage and interest expense are visible in reported figures; balance sheet flexibility exists but debt load is non-trivial relative to cash, so capital allocation and debt management remain important over the next few years.

Earnings Analysis

  • Recent earnings snapshot (quarterly, as reported)
    • Total Revenue (latest quarter shown): 111.616B
    • Gross Profit: 20.012B
    • Operating Income: 5.150B
    • EBITDA: 6.193B
    • Net Income (continuing ops, before minority interests): 3.406B
    • Net Income (including noncontrolling interests): 3.572B
    • Diluted EPS: 3.74
    • Basic EPS: 3.764
    • Normalized Income: ~3.441B
    • Total unusual items: small in magnitude (net negative impact from unusual items in some periods)
    • Tax effect of unusual items: negative in several periods (minimally impactful overall)
    • Reconciled depreciation: ~1.084B
  • EPS Trend (selected points)
    • 0q (current quarter): 2.86935
    • +1q (prior quarter): 2.06206
    • 0y (year-ago quarter): 16.23467
    • +1y (12-month horizon indicator): 18.01123
    • Interpretation: The presented quarterly EPS values show fluctuation that appears large between quarters and year-ago baselines, reflecting the influence of non-operating items, tax effects, and potential quarter-specific adjustments. The normalized income suggests a steadier underlying profitability path, but the raw quarterly EPS figures can be volatile due to items that are not part of ongoing operations.
  • EPS revisions (surveys of analyst sentiment)
    • 0q horizon: downgrades in the last 30 days (1 downgrade in the 30-day window)
    • +1q horizon: one upgrade in the last 30 days
    • 0y horizon: one downgrade in the last 30 days
    • +1y horizon: two upgrades in the last 7–30 days and three downgrades in the last 30 days
    • Net takeaway: mixed revisions with a tilt toward downgrades in longer horizons, suggesting some caution on long-term EPS acceleration relative to prior expectations.
  • Earnings quality
    • Revenue base is large and resilient (Total Revenue ~111.6B in the latest snapshot vs prior quarter), with stable gross margins around 21% and reasonable operating leverage.
    • The presence of unusual items and tax effects in reported quarters can distort GAAP EPS in the near term; normalized earnings provide a clearer view of sustainable profitability.
    • The company demonstrates the ability to generate meaningful EBITDA relative to net income, indicating some structural differences between operating income and cash-based metrics.

Technical Analysis

  • Price action and trend context
    • Current price: 358.77
    • 50-day moving average (MA): 307.6
    • The price sits well above the 50-day MA, signaling a positive near-term trend with a growing gap to the short-term moving average.
  • Momentum and oscillators
    • RSI (14) recently around 68.7 (approaching overbought territory). Elevated RSI suggests potential for short-term consolidation or a minor pullback before resuming the uptrend.
    • MACD (12,26,9): Last readings show MACD around 11.8 with a Signal of 12.3, a modest negative MACD histogram on the most recent date, indicating near-term softness and a potential short-term pullback or consolidation.
  • Support and resistance context
    • Immediate support: around the 50-day MA (roughly 308) and a nearby floor near 300–315 from recent price structure.
    • Immediate resistance: around recent highs near 360–362, with the psychological and technical upside continuing beyond the 50-day MA given the current uptrend.
  • Takeaway: The stock is in an uptrend with strong longer-term support around the 50-day MA region, but the RSI near overbought and a slightly negative MACD cross imply the possibility of short-term consolidation before resuming upside momentum if earnings and macro catalysts support it.

Analyst Consensus & Price Targets

  • Current consensus and levels
    • Current price: 358.77
    • Target low: 198.00
    • Target median: 331.00
    • Target high: 626.00
    • Target mean (average): 341.33
    • Number of analysts: 24
  • Interpretation
    • The current price sits above the median target of 331 but near the mean target (341). In other words, the market currently trades above the mid-point of the analyst dispersion, implying potential upside risk if markets re-rate the stock higher but a lack of urgency to chase above-mean targets unless catalysts emerge.
    • The high target of 626.00 indicates substantial upside implied by some analysts, but the breadth of targets also signals notable upside risk if the company meets or exceeds elevated growth expectations and margin expansion.

Price Target Analysis (Short, Mid, Long-Term)

  • Short-Term (3 months): Target around 331 (median)
    • Justification: Near-term price action could see consolidation given RSI is near overbought levels and the MACD shows a marginal negative slope. The stock is trading above the median target and could pull back to ~331 as a reversion toward consensus fundamentals; a closer look at upcoming quarterly earnings and regulatory news will be key drivers.
    • Key drivers: near-term earnings release context, macro health care demand, and reversion toward fair-value multiples.
  • Mid-Term (12 months): Target around 341 (mean/consensus)
    • Justification: The mean target (~341) sits roughly in line with current price, suggesting a modest total return if the multiple re-rates in line with consensus earnings growth. Improvements in earnings quality and continued cash generation could support a steady multiple expansion.
    • Key drivers: sustained revenue growth, margin stabilization, ongoing buybacks/dividends, and favorable regulatory environment in healthcare.
  • Long-Term (3+ years): Target up to 626 (high)
    • Justification: A high-end case assumes meaningful earnings acceleration and potential multiple expansion as healthcare services scale, cost discipline improves margins, and growth in Medicare/MA volumes intensifies. The long-run upside implies a potential near-doubling-plus from current levels if structural catalysts materialize.
    • Key drivers: demographic tailwinds, improved operating leverage, potential payer mix shifts benefiting margins, and favorable long-run cash-flow generation.

Key Risks & Opportunities

  • Major risks
    • Regulatory and reimbursement changes impacting margins or growth (e.g., rate changes in Medicare/MA programs).
    • Competition and pricing pressure within managed care and provider networks.
    • Integration/friction risk in any acquisitions or large-scale shifts in care delivery models.
    • Macro sensitivity in health care spending and unemployment affecting employer-provided plans.
  • Key opportunities
    • Ongoing buyback and dividend resilience; capital allocation potentially enhances shareholder value.
    • Growth in Medicare Advantage and other value-based care initiatives could improve membership mix and profitability.
    • Robust cash generation enabling debt reduction or further strategic investments.

Investment Recommendation

  • Overall view: Hold with a constructive tilt given the defensive profile, strong balance sheet, and multi-faceted earnings dynamics. The stock trades with a favorable forward P/E and a solid dividend yield, yet near-term momentum flags caution due to RSI approaching overbought territory and a modest MACD signal.
  • Time horizon: 12–24 months
  • Expected return potential:
    • Base case: roughly flat to low single-digit upside (~0% to +8%), driven by continued earnings stability and cash generation.
    • Bull case: meaningful upside potentially approaching the high target (626) if earnings growth accelerates and multiples re-rate, implying potential upside in the mid-60% range or higher from current levels if all catalysts align.
    • Bear case: downside risk to the median/low targets (roughly ~-10% to -25%) if near-term momentum fades and revisions trend negative on a sustained basis.
  • Quantitative framing: With current price around 359 and a mean target of ~341, the baseline implies modest downside risk to near-term targets if the stock retraces toward consensus. However, with a robust balance sheet and stable earnings potential, upside remains if earnings quality improves and the market re-rates multiples higher.

Analyst Coverage and Targets (Numerical snapshot)

  • Current price: 358.77
  • Target low / median / high: 198.00 / 331.00 / 626.00
  • Target mean: 341.33
  • Analysts covering: 24

Tables: Selected Numerical Data

  • Valuation and risk metrics

    • Market cap: 324,928,503,808
    • Enterprise value: 383,456,641,024
    • Trailing P/E: 15.537894
    • Forward P/E: 11.998997
    • P/B: 3.427728
    • ROE: 21.653%
    • ROA: 6.464%
    • Profit margin: 5.037%
    • Gross margin: 20.842%
    • Operating margin: 4.614%
    • Debt/Equity: 75.577
    • Total cash: 32,020,000,768
    • Total debt: 79,192,997,888
    • Dividend yield: 2.45%
    • 5-year avg dividend yield: 1.47%
    • Beta: 0.478

  • Earnings snapshot (selected items, latest period shown)

    • Total Revenue: 111,616,000,000
    • Gross Profit: 20,012,000,000
    • Operating Income: 5,150,000,000
    • EBITDA: 6,193,000,000
    • Net Income (continuing ops): 3,406,000,000
    • Diluted EPS: 3.74
    • Basic EPS: 3.764
    • Normalized Income: 3,441,875,000
    • Total Unusual Items: -41,000,000
    • Tax Effect of Unusual Items: -5,125,000

  • EPS trend (selected periods)

    • 0q: current 2.86935; 7 days ago 2.86935; 30 days ago 2.81172; 60 days ago 4.65065; 90 days ago 5.14849
    • +1q: current 2.06206; 7 days ago 2.06206; 30 days ago 2.10168; 60 days ago 4.02003; 90 days ago 4.45799
    • 0y: current 16.23467; 7 days ago 16.24223; 30 days ago 16.24223; 60 days ago 16.21862; 90 days ago 22.15138
    • +1y: current 18.01123; 7 days ago 18.08738; 30 days ago 18.08392; 60 days ago 19.52943; 90 days ago 25.99375

  • EPS revisions (horizons)

    • 0q: upLast7days 0, upLast30days 0, downLast30days 1, downLast7Days 0
    • +1q: upLast7days 0, upLast30days 1, downLast30days 0, downLast7Days 0
    • 0y: upLast7days 0, upLast30days 0, downLast30days 1, downLast7Days 0
    • +1y: upLast7days 1, upLast30days 1, downLast30days 3, downLast7Days 0

Notes on data interpretation

  • GAAP EPS vs. normalized earnings can diverge meaningfully due to unusual items/tax effects observed in the earnings dataset. For sustainability assessment, focus on normalized income and EBITDA in addition to GAAP EPS.
  • The price targets imply a wide dispersion in analyst views (198–626), with most opinions clustered around a median/mean near the 331–341 area. Current price trading above the median, but near the mean, indicates that outcomes are sensitive to earnings quality and regulatory/regulatory-mavorable developments.
  • The 50-day MA is well below the current price, suggesting the path of least resistance is higher, but RSI and MACD near-term signals call for vigilance for a pullback or consolidation before continuing the move.

References to Data Provided

  • Price targets and mean/median/high consensus
  • Earnings summary and line items (Net Income, EBITDA, etc.)
  • EPS trend and revisions data
  • Technical indicators (50-day MA, RSI, MACD)
  • 50-day MA values and RSI/MACD readings are consistent with the last 60 days of data provided

If you’d like, I can

  • Build a more granular model (e.g., scenario-based targets with revenue and margin assumptions) and quantify the resulting probability-weighted returns.
  • Extend the chart annotations with additional technical levels (e.g., 200-day MA, recent swing highs/lows) or simulate reactions to specific catalysts (e.g., Medicare policy changes, MA growth, new product mix).
  • Create a concise executive summary slide deck with the above data for investor meetings.
Chart is loading...